Gibson Vance, host of the Beasley Allen Report, welcomes fellow Beasley Allen attorney and shareholder Frank Woodson to discuss the statin drug Lipitor and the dangers associated with its link to the development of Type 2 diabetes.
Woodson joined Beasley Allen in 2001 after being a general practitioner for 17 years at a general litigation firm in Mobile, Ala. Focusing his practice in the Mass Torts section of the law firm, Frank has been a leader in multiple drug litigations, including Baycol, Propulsid and Rezulin.
Lipitor, known as the best-selling prescription drug ever, was approved by the Food and Drug Administration (FDA) in 1996. The drug’s purpose was to help lower cholesterol; however, statin drugs like Lipitor have had a bad reputation for causing problems in the past. An example of a statin drug with frightening side-effects was Baycol; a statin drug that was discovered to be the cause of rapid muscle deterioration. Eventually, Baycol was removed from the market. Lipitor has been shown to increase blood sugar levels in people who use the drug, putting them at greater risk of developing Type 2 diabetes. The FDA has warned that other statin drugs may pose the same Type 2 diabetes risk as Lipitor. Those especially vulnerable are postmenopausal women who are not considered overweight.